All In Biotech

NDA 218571 · Milestone Pharms USA

Cardamyst

Etripamil · Nasal

Novel

CDER novel approval, Dec 12, 2025: To treat episodes of paroxysmal supraventricular tachycardia

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Dec 12, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

6 Phase 3, 2 recruiting

FAERS reports

11

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults ( 1 ).

Mechanism: Etripamil is an L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting reentry at the AV node, etripamil can restore sinus rhythm in patients with PSVT.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 12, 2025 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • CARDAMYST · ETRIPAMIL 70MG · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Etripamil" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nasal discomfort4
  • oropharyngeal pain3
  • drug ineffective2
  • hypertension2
  • hypotension2
  • nasal dryness2
  • rhinalgia2
  • wrong technique in product usage process2
  • contraindicated product prescribed1
  • drug effect less than expected1
  • dysgeusia1
  • epistaxis1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Milestone Pharms USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.